All analyses
AI analysis

Ceylon Hospitals Plc: research report

Moderately undervaluedbullishNov 13, 2026

Evidence points bullish: September profit grew 44.1% as operating margin widened, reinforcing a moderately undervalued starting point. The catch is that the share is more expensive than its own history on both P/E and P/B.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • September-quarter net profit rose 44.1% year-on-year, with operating margin improving to 14.9% from 13.5%.
  • Debt was 11.2% of owners' equity at March 2026 and operating profit covered interest 8.07 times.
  • The market-wide valuation score is 72 of 100, placing CHL in the moderately undervalued band.

Against this. At 11.44 times earnings, the voting share is more expensive than 82% of days since January 2019.

Operating margin
14.9%
from 13.5% a year earlier
Net margin
10.6%sector 13.0%
from 9.4% a year earlier, revenue +26.8%
Return on equity
8.7%
twelve months to Sep 30, 2026, unaudited
P/E
11.4sector 11.8
earnings Rs 5.68 per share, year to Mar 2026
P/B
0.88sector 1.36
book Rs 73.57 per share
Dividend yield
1.69%sector 0.00%
19.4% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 13, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Ceylon Hospitals, operating as Durdans, runs a private hospital alongside diagnostic, laboratory, clinical-services and medical-education operations across Sri Lanka. The latest quarter shows a business whose revenue and operating profit both accelerated, with the improvement reaching net profit rather than being confined to accounting items.

The company completed a 1:4 share split in March 2026. This changed per-share figures mechanically but did not alter the size of the underlying hospital and diagnostics business.

Price performance

At LKR 65.00 on 13 November 2026, the voting share had gained 14.2% over one month against 10.3% for the ASPI, but was down 8.3% over one year versus a 4.7% ASPI decline. The 1:4 split means these returns are restated onto today's share basis; the unadjusted screen-price comparison would wrongly treat the split as a loss.

The share sits 25.9% of the way through its 52-week range, closer to the low than the high. Its three-year record contains one fall of 15% or more, the deepest 43%, which has not yet recovered. Liquidity is a material constraint: median daily turnover was LKR 208,000, and a LKR 1 million order is more than everything that trades on a typical day, 481% of it.

Valuation

The voting line trades at a P/E of 11.44 times, or LKR 11.44 paid for each LKR 1 of trailing profit, and a P/B of 0.88 times, or 88 cents for each rupee of net assets. The latest audited return on equity was 8.0%, so the sub-book valuation is not being supported by an especially high return on the equity base.

Against five healthcare peers, CHL's P/E is above the 10.27 median while its P/B is below the 1.50 median. Its 1.7% dividend yield is below the sector's 2.7% median; the payout nevertheless increased from LKR 0.50 in FY2024 to LKR 1.00 in FY2025 and LKR 1.10 in FY2026.

The apparent value case conflicts with CHL's own record. The P/B is more expensive than 87% of days since January 2019 and the P/E is more expensive than 82% of days since January 2019. A buyer at this price is also relying partly on the September quarter, which supplied 31.4% of trailing EPS; at its year-ago net margin, the P/E would be 11.9 times rather than 11.4 times.

News and sentiment

Direct coverage was normal but limited, with three material articles in the past 90 days, all classified neutral. Articles reported on 19 October that Durdans exited Digital Health, selling its 5.26% Doc990 stake; the disclosed reports do not state the proceeds received by CHL or the earnings effect, so the financial consequence cannot be sized.

The LKR 1.10 first interim dividend went ex-dividend on 1 June 2026, so a buyer today does not receive it.

Financials

September-quarter revenue rose 26.8% year-on-year to LKR 3.4 billion, while operating profit rose 39.9% and net profit increased 44.1% to LKR 364 million. Profit therefore grew faster than sales, meaning the quarter generated more earnings from each rupee of patient-care and diagnostic revenue.

Gross margin was 44.2% versus 60.7% a year earlier, operating margin was 14.9% versus 13.5%, and net margin was 10.6% versus 9.4%. The gross margin was the worst among seven comparable September quarters, but the operating margin was middling among those seven and among the best two of the last 12 quarters overall. The improved operating margin, rather than gross margin, drove the stronger profit conversion.

Below operating profit, finance costs, tax and other items absorbed LKR 145 million, up from LKR 111 million a year earlier, so not all of the operating gain reached shareholders. Equity rose to LKR 13.3 billion from LKR 12.3 billion a year earlier. The September filing used 167.6 million shares, four times the pre-split count, reflecting the March subdivision rather than a dilution of the business.

Risks

The most immediate practical risk is liquidity rather than leverage: only LKR 208,000 changed hands in a median session over the past 60 days, making a LKR 1 million position a large part of normal trading activity. The share's record also includes a 43% fall that took nine months to bottom and remains unrecovered.

Operating risk is concentrated in the sharp gross-margin deterioration. September gross margin was 44.2%, the weakest of seven comparable September quarters, even though operating and net margins improved. This leaves the stronger earnings result dependent on operating-cost control and revenue growth offsetting the lower gross profit retained from each rupee of sales.

Balance-sheet risk is comparatively contained. At March 2026, gearing was 11.2%, meaning debt equalled 11 cents for each rupee of owners' equity; interest cover was 8.07 times, meaning operating profit covered the interest bill about eight times. The current ratio was 1.47 times, with short-term assets including receivables and inventories exceeding bills due within a year, and operating cash flow was 1.07 times operating profit. Minority shareholders received 9.6% of group profit, so group profit is modestly larger than the profit attributable to the ordinary shares being valued.

Outlook

As at 13 November 2026, the next defined catalyst is the interim filing for the quarter ending 31 December 2026, expected between 5 and 14 February 2027. It will show whether the September increase in revenue and operating profit continued and whether the weak gross-margin reading was offset by the rest of the cost structure.

The data cannot quantify the effect of the Doc990 disposal because CHL's sale proceeds and any resulting gain or loss were not disclosed in the supplied coverage. Healthcare-sector reporting also provides no company-specific evidence on how broader fuel-price and inflation developments have affected Durdans.

About this report. Generated on Nov 13, 2026 from market data up to Nov 13, 2026, 3 material news articles over 90 days and financials to Sep 30, 2026, and scored 72 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports